The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Home office licence and form of sales will send this rocketing.
My expectation is double the IPO price so looking for 330p which seems reasonable after progress made.
Out.
good luck hope it goes higher
Excellent day today. GLA
I never exspected this kind of rise before the Home Office Licence anouncment. Low share float and potential blue sky company being the first in the uk to be able to grow high THC medical cannabis. What’s your target because mine is way about 88p.
This has classic Friday pump and dump, why the rise ? Will close < 75
Can't get a quote just now
The disappointed IPO sellers may have sold out leaving only those for the long haul.
Nice price action today on small volume.
Once the license is received this looks like it will fly.
Seems very quiet right now. Keep nibbling away I guess until something exciting lands.
Yes,I guess a full HO license will be required before CEL production team can fire the starters gun.
I was the only ouside shareholder at the AGM.
are there any shareholder perks, free product perhaps??? the AGM must be fun :)
PS topped up 5k today but showing on here as a sell
From that RNS... the market will need confirmation of the renewal of the home office licence, as it expired on the 12th Jan 2023 before we see any real traction and interest.
Celadon will require receipt of confirmation from the Home Office that they have updated its current Home Office licence before they will be able to supply its GMP API to third parties. The Company is informing the Home Office of the receipt of its GMP registration. Celadon's current Home Office licence permits it to legally grow high-THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA; during 2022, Celadon achieved seven successful harvests. Whilst there is no guarantee that the Home Office will update the current licence, nor any timeframe for this, the Directors are confident that the licence will be updated in due course. The Company has worked closely with the Home Office for four years, including securing updates to its licence, and had the conversation about updating the licence for GMP at the Home Office's last site inspection.
and from the proposed acquisition document dated 28th feb 2022.
On 23 July 2021, Vertigrow's subsidary, CPL received a Home Office Licence following approval from the Medicines and Healthcare products Regulatory Agency (the "MHRA") to apply for the licence, allowing it to legally grow medicinal cannabis in the UK for the purpose of producing test batches of cannabis oil to support its application to the MHRA for registration as a manufacturer of medicinal product APIs. This licence was renewed on 12 January 2022 for a 12 month period and as part of that renewal CPL changed its analytical testing partner. The process of obtaining this licensing is complex, took over two years, required material investment and is technically extensive. The Directors and Proposed Directors believe this is one of the first such Home Office Licences granted in the UK. Following the satisfactory production of test batches of cannabis oil, Celadon will apply for MHRA registration and if this is successfully received, Celadon will also apply for a new licence from the Home Office. Once received, the new Home Office licence would be required to be renewed annually. The receipt of MHRA registration and a new Home Office licence will enable the business to then supply medicinal cannabis (in the form of an API to manufacturers of finished medicinal products, which in this case is an extracted oil used in the finished pharmaceutical product) with a high THC content in the UK, allowing it an opportunity to enter what is expected to be a substantial, extensively regulated and fast-growing UK market.
Yes, I do think it is time to build a decent stake now, and I'm starting to build mine.
Can't wait to sample the products!
It will go loud soon, I wouldn't be surprised if it will bag within few days. Dyor, gla
I agree. The uncertainty and major risk of failure has been passed and the market reaction is muted.
GMP registration understood to be the first such registration of a UK pharmaceutical facility for high ?9-tetrahydrocannabinol ("THC") cannabis API since the legalisation of medical cannabis in 2018
I think the market is saying ''this is a nice story, the approval is in place and the upside is therefore considerable, but the last results show £11k turnover, and IP only has real value when it is commercialised.''
I guess I am in for a couple of years with this, and remember what happened to GWP....eventually.... after a long and rocky journey.
Market lately react after a day, or two. Only my opinion
Is there enough cash to 2024 when revenues start or they need more? I think the market is saying "more"
Somewhat disappointing market reaction to the positive news; this will take time, but I think there is huge upside.
Bit of interest here today
Nice article written yesterday
https:// www . europeanbusinessreview . com/top-4-pharmaceutical-stocks-to-watch-this-year
It's getting ready to launch.